Breast Cancer

Multilineage Hematopoietic Therapy is Safe in Chemotherapy Patients

Published in Women's Health Weekly, November 30th, 2000

Maret Pharmaceuticals, Inc., reported positive Phase I clinical results that demonstrate the potential of MARstem^tm as a multilineage hematopoietic therapy (multiple blood cell stimulant) to treat or prevent pancytopenia (a reduction in different types of blood cells) following chemotherapy in breast cancer patients.

The study was selected as a late breaking abstract at the 11th National Cancer Institute - European Organization for Research and Treatment of Cancer - American Association for Cancer Research (NCI-EORTC-AACR) Symposium on New Drugs in Cancer Therapy, held November 7-10, 2000, in Amsterdam, The Netherlands.

The study was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2000-11-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry